TY  - GEN
AU  - Leducq,Sophie
AU  - Caille,Agnès
AU  - Barbarot,Sébastien
AU  - Bénéton,Nathalie
AU  - Bessis,Didier
AU  - Boccara,Olivia
AU  - Bursztejn,Anne-Claire
AU  - Chiaverini,Christine
AU  - Dompmartin,Anne
AU  - Droitcourt,Catherine
AU  - Gissot,Valérie
AU  - Goga,Dominique
AU  - Guibaud,Laurent
AU  - Herbreteau,Denis
AU  - Le Touze,Anne
AU  - Léauté-Labrèze,Christine
AU  - Lorette,Gérard
AU  - Mallet,Stéphanie
AU  - Martin,Ludovic
AU  - Mazereeuw-Hautier,Juliette
AU  - Phan,Alice
AU  - Plantin,Patrice
AU  - Quéré,Isabelle
AU  - Vabres,Pierre
AU  - Bourgoin,Hélène
AU  - Giraudeau,Bruno
AU  - Maruani,Annabel
TI  - Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial
SN  - 1745-6215
PY  - 2020///0820
KW  - Administration, Cutaneous
KW  - Adolescent
KW  - Adult
KW  - Child
KW  - Clinical Trials, Phase II as Topic
KW  - Dermatologic Agents
KW  - administration & dosage
KW  - Double-Blind Method
KW  - France
KW  - Humans
KW  - Lymphangiectasis
KW  - drug therapy
KW  - Lymphatic Abnormalities
KW  - Multicenter Studies as Topic
KW  - Quality of Life
KW  - Randomized Controlled Trials as Topic
KW  - Sirolimus
KW  - Skin Diseases
KW  - TOR Serine-Threonine Kinases
KW  - metabolism
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial Protocol; Journal Article
UR  - https://doi.org/10.1186/s13063-019-3767-8
ER  -